Responses
Regular and Young Investigator Award Abstracts
Clinical Trial In Progress
660 Phase 2 Study to evaluate the triplet combination of pemetrexed plus etrumadenant and zimberelimab in patients with previously treated advanced or MTAP-deficient metastatic urothelial carcinoma (mUC)
Compose a Response to This Article
Other responses
No responses have been published for this article.
